Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalCCEL +0.84%58 Earnings Yield (Joel Greenblatt) % is -1.89% as of May. 2026. GuruFocus rates CCEL with a GF Score™ of 58/100 and a GF Value™ of $5.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 73.35% on this metric.
Cryo-Cell International's Enterprise Value for the quarter that ended in May. 2026 was $32.97 Mil.
Cryo-Cell International's EBIT for the trailing twelve months (TTM) ended in May. 2026 was $-0.62 Mil. Cryo-Cell International's Earnings Yield (Joel Greenblatt) for the quarter that ended in May. 2026 was -1.89%.
The historical rank and industry rank for Cryo-Cell International's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CCEL'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -24.16 Med: 7.12 Max: 14.75
Current: -1.79
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Cryo-Cell International was 14.75%. The lowest was -24.16%. And the median was 7.12%.
CCEL's Earnings Yield (Joel Greenblatt) % is ranked worse than 73.35% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 3.49
vs CCEL: -1.79
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cryo-Cell International's Forward Rate of Return (Yacktman) % for the quarter that ended in May. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Cryo-Cell International (AMEX:CCEL) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Cryo-Cell International Earnings Yield (Joel Greenblatt) % Related Terms
Cryo-Cell International Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International Earnings Yield (Joel Greenblatt) % Chart
For the Medical Care Facilities subindustry, Cryo-Cell International's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Earnings Yield (Joel Greenblatt) % falls into.
Cryo-Cell International Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Cryo-Cell Internationals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Nov. 2025 is calculated as
Cryo-Cell International's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.62 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -1.89% mean?
Cryo-Cell International (CCEL) has a Earnings Yield (Joel Greenblatt) % of -1.89% as of May. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #501 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 73.4%.
Is Cryo-Cell International's Earnings Yield (Joel Greenblatt) % too high?
Cryo-Cell International's current Earnings Yield (Joel Greenblatt) % is -1.89%. Based on the distribution chart, Cryo-Cell International ranks #501 out of 683 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Earnings Yield (Joel Greenblatt) % compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #501 out of 683 companies for Earnings Yield (Joel Greenblatt) %. This places Cryo-Cell International in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.49, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Earnings Yield (Joel Greenblatt) % is -1.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $5.45, compared to a current price of $3.60 — trading 33.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -1.89%. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current Earnings Yield (Joel Greenblatt) % is -1.89% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $3.60 is trading 33.9% below its estimated GF Value™ of $5.45.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for CCEL:
Earnings Yield (Joel Greenblatt) %: -1.89%
GF Value™: $5.45 vs. price of $3.60 (33.9% below fair value)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for CCEL
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
